Generic
Vildagliptin + Metformin Hydrochloride

Description
Aptin M 50/500 is a combination oral hypoglycemic medication containing Vildagliptin 50mg and Metformin Hydrochloride 500mg. It is used to improve glycemic control in patients with type 2 diabetes mellitus who are inadequately controlled on monotherapy or are already using separate doses of Vildagliptin and Metformin Hydrochloride.

Benefits
Aptin M 50/500 effectively regulates blood sugar levels by enhancing insulin secretion and reducing glucagon levels. It helps lower fasting and postprandial glucose levels, improving beta-cell function and insulin sensitivity. Targeting different pathways involved in diabetes management provides dual benefits.

Ingredients
Each tablet contains Vildagliptin 50mg and Metformin Hydrochloride 500mg, along with excipients to support absorption and stability.

Uses and Doses
Adults should take one tablet twice daily, morning and evening, based on their current Metformin dose. Patients already on separate doses of Vildagliptin and Metformin can switch to this combination with the same dose. The total daily dose of Vildagliptin should not exceed 100 mg. Taking the tablet with food may reduce gastrointestinal discomfort associated with Metformin.

Side Effects
Common side effects include headache, dizziness, nausea, tremor, and hypoglycemia. In rare cases, patients may experience lactic acidosis, gastrointestinal discomfort, or hepatic dysfunction.

How to Use
Swallow the tablet whole with water. Take it simultaneously each day to reduce stomach upset, preferably with meals. Follow your doctor's instructions regarding diet and exercise while using this medication.

Pregnancy & Lactation
There are no well-controlled studies on the safety of this combination in pregnant women. It should only be used during pregnancy if the benefits outweigh the potential risks. It is unknown whether Vildagliptin and Metformin Hydrochloride pass into breast milk; therefore, it is not recommended for breastfeeding mothers.

Precautions and Warnings
Metformin accumulation may cause lactic acidosis, a rare but serious condition. Patients with kidney impairment, heart failure, or metabolic acidosis should not use this medication. Serum creatinine levels should be monitored regularly to ensure renal function remains normal. The medication should be discontinued before radiological studies involving contrast agents.

Safety Information
Patients should avoid excessive alcohol intake while taking Aptin M 50/500 as it may increase the risk of lactic acidosis. This medication should be used cautiously in elderly patients and those with hepatic impairment.

Indications
Aptin M 50/500 is indicated for patients with type 2 diabetes mellitus who require additional glycemic control beyond diet and exercise. It is beneficial for those inadequately controlled on Metformin or Vildagliptin alone.

Pharmacology
Vildagliptin inhibits DPP-4 enzyme activity, increasing incretin hormone levels, enhancing insulin secretion, and reducing glucagon production. Metformin improves insulin sensitivity and reduces glucose production in the liver, lowering blood sugar levels.

Therapeutic Class
Combination Oral Hypoglycemic Preparations.

Storage Conditions
Store below 30°C in a dry place, away from moisture and direct light. Keep out of reach of children.

3 FAQ

1. Can Aptin M 50/500 be taken with other diabetes medications?
   It should not be combined with other diabetes medications without a doctor's recommendation.
2. Does Aptin M 50/500 cause weight gain?
   It does not typically cause weight gain and may even support weight management.
3. Can I stop taking Aptin M 50/500 if my blood sugar is regular?
   No, stopping medication suddenly may cause blood sugar fluctuations. Consult a doctor before making any changes.

Disclaimer
This information is for reference and is not a substitute for professional medical advice. Always consult a doctor before using this medication.

Keywords: Aptin M, Vildagliptin, Metformin Hydrochloride, diabetes treatment, blood sugar control, oral hypoglycemic, type 2 diabetes medication, ACI Limited, DPP-4 inhibitor, biguanide, glycemic control, diabetes management, insulin regulation, combination diabetes therapy, sugar level control, diabetic care, glucose regulation, diabetic medicine, insulin sensitivity, beta-cell function, ACI diabetes.